The Food and Drug Administration has approved a new pill designed to manage persistently high cholesterol levels. This approval introduces a more convenient option for patients who face a high risk of cardiovascular disease and heart attacks.
Unlike traditional cholesterol-lowering injections, Merck’s Lipfendra offers a daily oral alternative. This can simplify the treatment regimen for individuals struggling with high cholesterol, potentially improving adherence to prescribed therapies and overall heart health.
Understanding the Cyclospora Outbreak and Its Connection to Sewage Contamination 
New Insights into PMOS and GLP-1 Drugs 
Public Health Challenges with Proposed Vaccination Order 
Understanding Medicare Extra Help and Its Benefits 
Trump’s Remarks on Childhood Vaccines Spark Debate 
CDC Reports Drug-Resistant Fungus Candida Auris Cases Across 27 States